Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31548905 | 0.94 | KMT2A (0.46) | KMT2AMGLLFAAHTRPV1MEN1 | |
| SCHEMBL3829326 | 0.89 | MGLL (0.54) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL30678099 | 0.88 | KMT2A (0.45) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL7912741 | 0.87 | KMT2A (0.53) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL3795684 | 0.85 | KMT2A (0.59) | KMT2AMEN1EPHX2MAPTRAB9A | |
| SCHEMBL14966279 | 0.85 | HTR2A (0.44) | KMT2AMGLLEPHX2HTR2AMAPT | |
| SCHEMBL30538270 | 0.84 | MGLL (0.44) | KMT2AMGLLFAAHTRPV1MEN1 | |
| SCHEMBL31476468 | 0.83 | KMT2A (0.42) | KMT2AMGLLEPHX2HTR2AMAPT | |
| SCHEMBL14685603 | 0.83 | KMT2A (0.56) | KMT2AMGLLFAAHTRPV1EPHX2 | |
| SCHEMBL30242885 | 0.83 | KMT2A (0.56) | KMT2AMGLLFAAHTRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841257-B2 | Inhibitors of STAT3 and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2010118309-A2 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | KMT2A 2506/4885MGLL 4616/4885FAAH 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.